Keros Therapeutics Target of Unusually Large Options Trading (NASDAQ:KROS)

Keros Therapeutics, Inc. (NASDAQ:KROS) saw some unusual options trading on Friday. Stock traders acquired 4,215 put options on the company. This is an increase of approximately 287% compared to the typical volume of 1,090 put options.

Analysts Set New Price Targets

Several research firms recently weighed in on KROS. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Keros Therapeutics in a report on Tuesday, April 1st. William Blair cut shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th. TD Cowen cut shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Oppenheimer lowered their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th. Finally, Truist Financial cut their price target on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.33.

Institutional Investors Weigh In On Keros Therapeutics

Large investors have recently made changes to their positions in the company. AlphaQuest LLC boosted its holdings in shares of Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after buying an additional 2,964 shares during the last quarter. Virtus ETF Advisers LLC boosted its stake in shares of Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after acquiring an additional 1,998 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Keros Therapeutics during the 4th quarter valued at $90,000. Exchange Traded Concepts LLC bought a new stake in shares of Keros Therapeutics during the 4th quarter valued at $99,000. Finally, CANADA LIFE ASSURANCE Co increased its stake in shares of Keros Therapeutics by 207.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company’s stock worth $116,000 after purchasing an additional 4,976 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Stock Performance

Shares of KROS stock traded down $0.25 during trading hours on Friday, reaching $12.00. The company had a trading volume of 752,705 shares, compared to its average volume of 756,844. The business has a fifty day moving average price of $10.88 and a 200-day moving average price of $31.11. Keros Therapeutics has a one year low of $9.12 and a one year high of $72.37. The firm has a market cap of $486.54 million, a PE ratio of -2.30 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. Equities research analysts forecast that Keros Therapeutics will post -4.74 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.